This article is 1 year old
Reaction to the study about the use of antivirals in monkeypox patients

A study published in The Lancet Infectious Diseases analyses the response of seven monkeypox patients diagnosed in the UK between 2018-2021, treated with the antivirals brincidofovir and tecovirimat.


25/05/2022 - 00:35 CEST
monkeypox virus illustration/ Adobe Stock

Monkeypox virus illustration. / Adobe Stock

Expert reactions

Mar Faraco sobre uso de antivirales contra viruela del mono - EN

Mar Faraco

President of the Association of Foreign Health Doctors (AMSE) and Head of the Foreign Health Service in Huelva

Science Media Centre Spain

It is interesting as a description but provides little or nothing, because of the very limited number of cases covered. There is a brief general summary, no comparison, no associated laboratory data on viral detection nor general test data, etc.

Specifically, brincidofovir was given quite late and in addition to not seeming to have much effect (perhaps also because of the delay?) it altered the liver tests. But with three cases and without knowing the dose, as they themselves say, it is not assessable (perhaps it is useful as a small clue to follow if it is decided to reuse).

As for tecovirimat, approved in 2022 by the EMA (European Medicines Agency), with only one case treated there is nothing real to say, although it does not contradict the data for which it has been authorised, and it has had no side effects.

The author has not responded to our request to declare conflicts of interest
The 5Ws +1
Publish it